Company Introduction
A bio company owning antibody fragment-based technology and development innovative biologics

SCIENTIFIC ADVISORY BOARD

Name Experience Remarks
Professor Ho-Jin, Kim

Currently, Chief Research Fellow, Clinical Medicine Research Department, Korea National Cancer Center

Previously, Director, Transitional Clinic Trial Department II, Korea National Cancer Center

Previously, Senior Research Fellow, Special Cancer Research Department, Korea National Cancer Center

Dr. of Medicine (Seoul National Univ., Korea)
Kristine Kim

Currently, Associate Professor, Medical and Bioscience College, Gangwon University

Previously, Invited Research Fellow, Scripps Korea Antibody Institute

Previously, Senior Research Fellow, Seattle Genetics (USA)

Ph.D. in Biochemistry (WSH Univ, USA)
Ph.D (Utah Univ, USA)
Professor Se-Ho Kim

Currently, Professor, Medical and Bioscience College, Gangwon University

Currently, R&D Strategy Directory, Industry-Academia Collaboration Unit, Gangwon University

Previously, General Research Institute, Green Cross Co., Ltd.

Dr. of Immunology (Weizmann Institute of Science Univ, ISRAEL)
CEO Sang-Gu Lee

Currently, CEO, D. D. Partners

Currently, Associate Professor, Medical College, Hanyang University

Previously, CEO, Future Medicine Co., Ltd.

Ph.D. in Veterinary Pathology (Tokyo University, Japan)

BD ADVISORY BOARD

Name Experience Remarks
Judith U. Kim

Rubin and Rudman Partner and Chair of IP Practice

Sterne, Kessler / Goldstein & Fox Associate and Partner

Potomac Law Group (Bio-pro. lawyer)
Shuihua Zhang

Shenzhen Sinobioway Xinpeng Deputy General Manager

Shenzhen AUSA Pharmcomed Molecular  Medicine Manager

CEO Young-Su Mun

Chemizen Inc, CEO

LG Int'l (Deutschland) GmbH, General Manager

BL&H USA, LLC CEO